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United States hospitals included in the ADHERE patient registry.
All beneﬁts were assumed to accrue in the index hospitalisation
and treatment-speciﬁc lengths of stay were estimated after
adjusting for prognostic indicators. A constant factor was used
to adjust US LOS estimates to reﬂect Swiss patterns. Age-speciﬁc
all-cause mortality at six months was derived from the literature.
Treatment costs are reported in 2003 Swiss francs (CHF) and
include: hospital per diems (from a sample of university hospi-
tals, and including physician costs) and medications for heart
failure. The base-case was estimated for patients aged 75 years
with moderate left ventricular dysfunction (ejection fraction
35–44%). RESULTS: For 1000 subjects admitted with ADHF,
the number of subjects surviving at six month was estimated to
be: 837 for initial treatment with nesiritide, 826 for dobutamine,
and 833 for milrinone. The total cost of treating these cohorts
is estimated at CHF 9.0 million for nesiritide, CHF 10.2 million
for dobutamine, and CHF 11.9 million for milrinone. CON-
CLUSIONS: Based on available data, the base-case shows that
nesiritide is at least as effective as inotrope therapy at reducing
mortality in persons admitted to hospital for ADHF. While the
acquisition cost of nesiritide is higher than that for the inotropes
nesiritide is less costly than inotropic therapy at six months in
Swiss university hospitals.
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OBJECTIVES: After 1990, it was recognised that the male pop-
ulation’s life expectancy increased relatively quickly. This elon-
gation was signiﬁcant in decreasing the mortality rate from
diseases of the circulatory system, mainly ischemic heart diseases.
METHODS: Regression cost analysis was used for analysis of
databases such as OECD Health Data, The Ministry of Health
and Statistic institution of the Czech Republic. RESULTS: From
the analysis it is evident that decreasing the concentration of cho-
lesterol in blood plasma of the Czech population (mainly HDL
cholesterol), an exponential increase in the number of people
undergoing cardio surgery and consumption of modern effective
drugs have all had positive effects. Use of antihypertensives in
the years 1994–2003 has increased by more than ten times.
Moreover, use of serum lipid reducing agents has increased sig-
niﬁcantly by more than 15 times since 1995. In 2002 pharma-
ceutical expenditures totaled 48,032 billion Czech crowns (1501
billion €). Use per inhabitant was 4681 Czech crowns (151€).
Cardiovascular drug use was 19.6% of total volume of drugs in
the year 2002. To save one year life in the general population
aged 0–69 years as a result decreasing mortality of ischemic heart
disease, marginal costs for drugs for cardiovascular diseases was
185,000 Czech crowns (5968€). CONCLUSIONS: Drugs for the
treatment of the circulatory system play a signiﬁcant role in drug
policy. The rate of reimbursement drugs from public resources
remains controversial and problems regarding drug policy in the
Czech Republic have not yet been resolved.
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OBJECTIVES: Patients with advanced nonsmall cell lung cancer
have been treated more intensively over the past decade. We
sought to see how changes in treatment intensity inﬂuenced sur-
vival and costs over time. METHODS: Patients ages 65+ diag-
nosed with early stage primary lung cancer were identiﬁed from
the SEER-Medicare database, a national clinical cancer registry
linked to Medicare claims ﬁles. Individuals were included if they
were diagnosed with locally advanced or metastatic (TNM stages
IIIb and IV) NSCLC between January 1, 1994 and December 31,
2001. Kaplan-Meier survival curves were ﬁtted for cohorts diag-
nosed each year from 1994 to 1999. Lifetime medical costs were
calculated for each chemotherapy group using the Kaplan Meier
sample average estimator. To determine whether there was a
trend in costs over time, a regression model was ﬁtted to lifetime
cost estimates for each successive cohort. RESULTS: A total of
14,875 patients met inclusion criteria (approximately 2300 per
year): 7411 (49.8%) stage IIIb and 7464 (50.2%) stage VI at
diagnosis. Proportion of patients receiving procedures in the ﬁrst
three months from diagnosis in 1994 and 1999 were as follows:
no procedure: 38%, 31%; surgery: nine percent (9%), seven
percent (7%), radiation therapy: 47%, 48%; chemotherapy:
27%, 43%. Survival for patients diagnosed in 1994 was 24% at
12 months and 11% at 24 months. Survival for those diagnosed
in 1999 was 27% at 12 and 12% at 24 months (log rank test
for equality, p = 0.57). In constant dollars, lifetime costs per
patient increased from $26,000 to $42,000 over this time period
(OLS regression for time trend: p < 0.002). CONCLUSIONS:
Costs of care for patients with advanced NSCLC diagnosed
between 1994 and 1999 increased 62% with no change in sur-
vival over this time period. Chemotherapy use accounted for the
majority of the increases in treatment intensity and cost.
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OBJECTIVES: Aim of this study was to evaluate cost-
effectiveness of rituximab + CHOP (R-CHOP) versus CHOP, in
patients affected by aggressive Non-Hodgkin lymphoma, in the
Italian NHS’ perspective. METHODS: The economic analysis is
based on an existing Markov model which was developed in
order to evaluate costs and effects for two hypotetical cohorts of
patients of age respectively higher and lower than 60 years, over
a time frame of 15 years after administration of chemotherapy.
The model is based on 5 health states (start therapy, complete
response, no response, progression, death) and combines efﬁcacy
data from published clinical trials (GELA-98-5) with utilities
from the literature and cost of therapies and medical follow-up
after chemotherapy, based on Italian treatment patterns. Costs
and effects were discounted respectively at 6% and 1,5%. Exten-
sive 1-way and Monte Carlo sensitivity analyses were conducted
in order to test the robustness of results. RESULTS: For the 2
cohorts (60+; 60-), incremental discounted Life Years Gained
with R-CHOP versus CHOP were respectively 1.08 and 1.02
years; incremental QALYs were 1.15 and 1.04; the incremental
cost/patient was 14.838€ and 13.938€; the incremental cost/LYG
was therefore 13.732€ and 13.717€ and the incremental
cost/QALY was 12.879€ and 13.362€, respectively for 60+ and
60- patients. CONCLUSIONS: The clinical advantage of R-
CHOP is supported by incremental cost/LYG and cost/QALY
ratios which fall well below all the thresholds commonly indi-
cated for these values both in the international and italian liter-
ature. R-CHOP is a substantial improvement in the treatment of
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aggressive NHL, at a reasonable cost, in the perspective of the
Italian NHS.
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OBJECTIVE: To determine the incremental cost-effectiveness
ratio (ICER) of imatinib versus IFN-a + Ara-C in newly diag-
nosed, chronic phase CML patients. METHODS: An economic
simulation model was developed in Microsoft Excel to estimate
expected total cost, survival and quality-adjusted survival for
patients treated with imatinib or IFN-a + Ara-C. This model is
based on data collected in the International Interferon versus
StI571 Study (IRIS) supplemented with data from international
literature and clinical experts. This model was adapted to the
Dutch situation. Utility weights and unit costs for medical
resources were assigned over time according to disease status and
treatment regimen. Long-term survival estimation was based on
historical relationships between cytogenetic response and life
expectancy with IFN-a. The analysis incorporated ﬁrst-order
and second-order uncertainty. Sensitivity analyses were also per-
formed to evaluate the inﬂuence of individual parameters. The
base year for the cost analysis was 2002 and only direct medical
costs were considered. RESULTS: Mean undiscounted survival
for patients receiving imatinib was estimated to be 15.20 years,
for the IFN-a + Ara-C patients this was 9.10 years. When both
costs and effects were discounted at 4% the incremental gain in
quality adjusted life years (QALYs) was 3.36. Incremental dis-
counted lifetime costs were €150,041 higher for patients receiv-
ing imatinib. This resulted in an ICER of 44,728€ per QALY
(95% conﬁdence interval; 41,044€, 49,505€). These results were
most sensitive to assumptions that affected relative duration and
costs of IFN-a or imatinib. CONCLUSION: The introduction
of imatinib as ﬁrst line treatment option results in a gain of 3.36
QALYs. However, this occurred at a considerable cost resulting
in an ICER of 44,728€ per QALY. In general, this ratio is con-
sidered to be high by Dutch registration and reimbursement
authorities. However, in the process of registration and reim-
bursement other aspects like budget impact and disease severity
also play an important role.
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OBJECTIVES: Patients with pain due to multiple bone metas-
tases who do not show satisfactory response to conventional
pain therapy radionuclide therapy leads to a pain reduction in
about 70–80% of patients. The objective here is to determine
cost-effectiveness ratios for this pain reduction in Germany.
METHODS: Based on the results of a double-blind, randomized,
placebo-controlled trial with 141 prostate cancer patients
radionuclide therapy is compared with conventional pain
therapy in an economic model considering German data from
literature and treatment recommendations. Incremental cost-
effectiveness is presented. The effectiveness is measured by “com-
plete pain response”. The model period is 16 weeks. Costs from
the perspective of the statutory health insurance, i.e. deducting
co-payments and discounts, are also considered. Sensitivity
analyses are conducted. RESULTS: The direct medical costs of
radionuclide therapy per patient (39% complete pain response)
sum up to 1990€ against 2200€ under conventional pain therapy
(17% complete pain response). Radionuclide therapy is domi-
nant. From sickness fundsx perspective the costs of radionuclide
therapy sum up to 1890€ compared to 1870€ under conventional
pain therapy. The incremental cost-effectiveness-ratio is 130€ per
complete pain responder. Sensitivity analyses reveal that the
exclusion of bisphosphonates from conventional pain therapy
lead to costs of therapy of 1170€. The respective incremental
cost-effectiveness-ratio is 3800€. From sickness funds’ perspec-
tive the costs of conventional pain therapy sum up to 990 EUR.
The respective incremental cost-effectiveness-ratio is 4210€.
CONCLUSIONS: Analgesia in patients with pain due to multi-
ple bone metastases is achieved at lower or nearly equal costs
under samarium in the base case. On the basis of this model
samarium could be a cost-effective treatment option for patients
with pain due to multiple bone metastases. However, to compare
cost-effectiveness ratios with other treatment options further
research is warranted.
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OBJECTIVE: To estimate the annual cost of managing dry eye
syndrome in secondary care in France, Germany, Italy, Spain,
Sweden and the UK from the perspective of the health care
system. METHODS: Published evidence on the epidemiology of
dry eye syndrome and associated resource use were collected.
This was supplemented with information on current clinical
practice and associated resource utilisation obtained by inter-
viewing specialists in the treatment of dry eye syndrome in each
country. National unit resource costs (in Euros at 2003/04 prices)
were applied to the resource use estimates to estimate the annual
secondary care cost. RESULTS: The estimated prevalence of dry
eye syndrome among patients reporting to specialists was great-
est in Germany (0.07%) and lowest in Sweden (0.02%). An esti-
mated 70% of sufferers were female in all six countries except
Germany (58% of sufferers). Proportionally more patients expe-
rienced mild dry eye syndrome in Germany (60% of sufferers),
whereas more patients experienced moderate and severe dry eye
syndrome in France (65% of sufferers). The total annual health-
care cost fo managing 1000 dry eye syndrome sufferers in sec-
ondary care ranged from 227,000€ in France to 915,000€ in the
UK. The cost per patient was highest in the UK due to the high
cost of prescriptions. Specialist visits were the main cost driver
in France and Spain, whereas it was prescriptions in Germany
and the UK and diagnostic tests in Italy and Sweden. A large
proportion of patients either self-treat or are managed by their
GP. Hence, our analysis reﬂects the prevalence and costs of those
patients severe enough to warrant treatment by a specialist.
CONCLUSIONS: Dry eye syndrome does not appear to impose
any signiﬁcant burden on the secondary healthcare providers in
the countries investigated.
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